Drug profile · INN
mobocertinib succinate
EXKIVITY
mobocertinib succinate (EXKIVITY) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Drug details — mobocertinib succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
mobocertinib succinate (EXKIVITY) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mobocertinib succinate?
mobocertinib succinate (EXKIVITY) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mobocertinib succinate?
EXKIVITY is a marketed brand name for mobocertinib succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mobocertinib succinate?
mobocertinib succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.